Administration occupational activities – Page 4

WHO, antibiotic pollution, antimicrobial resistance (AMR), wastewater management, solid waste management, pharmaceutical manufacturing, environmental health

Lilly’s Once-Weekly Insulin Efsitora Alfa Achieves Non-Inferiority in Four Phase 3 Trials

9 months ago talkbio0Tagged Administration occupational activities, Alfa, Diabetes, efsitora, Eli, Eli Lilly, Hemoglobin A1c measurement, Insulin, insulin therapy, non-inferiority, once-weekly, Phase 3 trials

Eli Lilly, efsitora alfa, once-weekly insulin, diabetes management, Phase 3 trials, non-inferiority, A1C reduction, insulin therapy.

Eli Lilly’s Weekly Insulin Efsitora Alfa Shows Promising Results in Late-Stage Trials

9 months ago talkbio0Tagged Administration occupational activities, Alfa, Diabetes, efsitora, Eli, Eli Lilly, Insulin, insulin therapy, Phase 3 Clinical Trials, QWINT-1, QWINT-3, Weekly

Eli Lilly, weekly insulin, efsitora alfa, type 2 diabetes, Phase III trials, QWINT-1, QWINT-3, insulin therapy, diabetes management

Launching a Product in Europe: Understanding Supply Chain Cost Drivers

9 months ago talkbio0Tagged Administration occupational activities, European (ethnic group), Financial cost, Market, Reusable Drivers, Risk, Supply Chain Cost Analysis, supply chain management

Supply Chain Cost Analysis, European Market, Cost Drivers, Supply Chain Management, Risk Management

Alaskans Can Virtually Manage Diabetes Risk for Free with Omada Health

10 months ago talkbio0Tagged Administration occupational activities, Alaska, Diabetes, Free Program, Omada Health, Virtual Chronic Care

Omada Health, Diabetes Management, Virtual Chronic Care, Alaska, Free Program

Cardurion Pharmaceuticals Raises $260M in Series B Funding to Challenge Statin-Dominated Cardiovascular Market

11 months ago talkbio0Tagged Administration occupational activities, Ascenta Capital, biotech, Blue color, Capital, Capital Management, Cardiovascular system, Cardurion, Farallon, fidelity, Genus: Digitalis, Granulovirus, Healthcare Opportunities, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Invus, Millennium, NEA, Research Company, Series B

Cardurion Pharmaceuticals, Series B Funding, Cardiovascular, Statins, Biotech, Bain Capital, Ascenta Capital, NEA, GV, Fidelity Management & Research Company, Millennium Management, Farallon Capital Management, Invus, Blue Owl Healthcare Opportunities, Delos Capital, Digitalis Ventures